124 completed, 17 unknown, 14 terminated, 10 withdrawn. 177 Phase 3, 9 Phase 2.
Follow Chronic Obstructive Pulmonary Disease: new trials by email Literature Review of Chronic Obstructive Pulmonary Disease trials Research Report on Chronic Obstructive Pulmonary Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease Verducatib, Placebo matching verducatib - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 1800 | 2027-03-10 | 2026-11-10 |
| Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 1252 | 2027-01-30 | 2026-10-26 |
| A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD) Lunsekimig - Chronic Obstructive Pulmonary Disease | Phase 3 | Enrolling by invitation | Sanofi | 1508 | 2026-09-16 | 2026-10-21 |
| Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2 - Chronic Obstructive Pulmonary Disease, COPD | Phase 3 | Recruiting | AstraZeneca | 59 | 2026-05-05 | 2026-10-16 |
| Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 800 | 2026-04-14 | 2026-09-28 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype Lunsekimig, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Sanofi | 942 | 2025-09-17 | 2026-10-23 |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Lunsekimig, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Sanofi | 942 | 2025-09-16 | 2026-10-19 |
| Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease TQC3721 Suspension for inhalation, Placebo of TQC3721 Suspension for Inhalation - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 666 | 2025-09-01 | 2025-09-10 |
| A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease CM310, Placebo - Chronic Obstructive Pulmonary Disease | Phase 2 / Phase 3 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 884 | 2024-09-13 | 2024-08-14 |
| Tadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease Tadalafil, Placebo - Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 200 | 2024-02-01 | 2026-08-20 |
| A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD Itepekimab (SAR440340), Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Sanofi | 669 | 2024-01-11 | 2026-09-18 |
| A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 171 | 2023-10-24 | 2026-03-05 |
| N-acetylcysteine (NAC) for the Treatment of Acute Exacerbation of COPD N-acetylcysteine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Unknown | Queen Mary Hospital, Hong Kong | 80 | 2023-09-18 | 2023-11-18 |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Astegolimab - Chronic Obstructive Pulmonary Disease | Phase 3 | Active not recruiting | Hoffmann-La Roche | 2000 | 2023-06-28 | 2026-11-13 |
| A Study to Evaluate the Efficacy and Safety of Ensifentrine for 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Ensifentrine, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Nuance Pharma (shanghai) Co., Ltd | 526 | 2023-03-10 | 2025-06-04 |
| The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.) Conventional rehabilition treatment(e.g leaflet) educated by hospital, Digital treatment based on Respiratory Rehabilitation Software - Respiratory System Disease, Chronic Obstructive Pulmonary Disease | Phase 3 | Unknown | Lifesemantics Corp. | 100 | 2022-01-13 | 2022-03-29 |
| Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICU Methylprednisolone, Placebos - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Versailles Hospital | 440 | 2021-10-25 | 2026-10-23 |
| Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination (2 inhalations) via pMDI, Salbutamol 100 mcg Inhaler (2 inhalations) + Ipratropium 20 mcg Inhalation Aerosol (2 inhalations) Free Combination via MDI - Chronic Obstructive Pulmonary Disease | Phase 3 | Withdrawn | Neutec Ar-Ge San ve Tic A.Ş | 2021-09-03 | 2021-09-13 | |
| A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER) Experimental: CHF6001 1600µg, Experimental: CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 4710 | 2021-07-14 | 2025-12-17 |
| A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) CHF6001 1600µg, CHF6001 3200µg, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Terminated | Chiesi Farmaceutici S.p.A. | 3973 | 2021-07-12 | 2026-02-02 |
Showing 20 of 177. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (177) · Bronchitis, Chronic (14) · Emphysema (14) · Lung Diseases (12) · Lung Diseases, Obstructive (10) · Dyspnea (7) · Hypertension, Pulmonary (6) · Diabetes Mellitus (4) · Respiratory Insufficiency (4) · Asthma (3) · Motor Activity (3) · Respiratory Tract Diseases (3) · Altitude Sickness (2) · Carcinoma, Non-Small-Cell Lung (2) · Heart Failure (2)
Chronic Disease (177) · Disease Attributes (177) · Pathologic Processes (177) · Pathological Conditions, Signs and Symptoms (177) · Respiratory Tract Diseases (174) · Lung Diseases, Obstructive (167) · Lung Diseases (165) · Bronchial Diseases (18) · Infections (18) · Respiratory Tract Infections (16) · Respiration Disorders (15) · Bronchitis (14) · Signs and Symptoms (11) · Signs and Symptoms, Respiratory (10) · Cardiovascular Diseases (9)
Formoterol Fumarate (22) · Glycopyrrolate (15) · Tiotropium Bromide (14) · indacaterol (13) · Budesonide (10) · indacaterol-glycopyrronium combination (10) · Albuterol (9) · Salmeterol Xinafoate (8) · aclidinium bromide (8) · Roflumilast (6) · Budesonide, Formoterol Fumarate Drug Combination (5) · Inhalation (5) · Azithromycin (4) · Beclomethasone (4) · Fluticasone-Salmeterol Drug Combination (4)
AstraZeneca (25) · Novartis Pharmaceuticals (24) · Chiesi Farmaceutici S.p.A. (11) · Novartis (8) · Sanofi (8) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Sumitomo Pharma America, Inc. (5) · Pearl Therapeutics, Inc. (3) · Wim Janssens (3) · Assistance Publique - Hôpitaux de Paris (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Dey (2) · Emphasys Medical (2) · Flinders University (2) · Henan University of Traditional Chinese Medicine (2)
United States (67) · Germany (36) · Canada (34) · United Kingdom (32) · Hungary (30) · Poland (28) · Spain (27) · France (26) · Italy (24) · China (22) · South Korea (22) · Argentina (21) · Belgium (20) · Netherlands (20) · Czechia (19)
Esther Garcia, MD (6) · Colin Reisner, MD (3) · David C Currow, MD, PhD (2) · Jiansheng Li, Professor (2) · John Connett (2) · Jorgen Vestbo, MD (2) · Nicholas Anthonisen (2) · William Vandivier, MD (2) · Wim Janssens, MD PhD (2) · Adrian R Martineau, MRCP (1) · Ajay K Nooka (1)
PMID 42551404, PMID 25670896, PMID 29331313, PMID 21272339, PMID 22003288, PMID 22177371, PMID 22206353, PMID 22383665, PMID 23020650, PMID 24156566, PMID 26024688, PMID 28419462, PMID 28993871, PMID 32021148, PMID 32450869, PMID 35815359, PMID 37364283, PMID 39106052, PMID 39197510, PMID 39854278, PMID 39894389, PMID 41794122, PMID 42153327, PMID 42337097, PMID 17290043, PMID 17711594, PMID 17908710, PMID 17962632, PMID 18535254, PMID 18535255, PMID 18641094, PMID 19228428, PMID 19232039, PMID 19537837, PMID 19716961, PMID 19882497, PMID 19910177, PMID 20008582, PMID 20018959, PMID 20090057, PMID 20102307, PMID 20154234, PMID 20211002, PMID 20214820, PMID 20522841, PMID 20536364, PMID 20860505, PMID 20965712, PMID 21227674, PMID 21397482
2009 (6), 2008 (2), 2018 (2), 2023 (2), 2014 (1), 2017 (1), 2019 (1), 2025 (1), N01HR761971 (1), P30CA138292 (1), R01HL034019 (1), R01HL071022 (1), U01HL050267 (1)